Contact
searchSearch
HMP Global
Login

Prostate Cancer

Prostate Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Kim Chi, MD
Videos
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
Kim Chi, MD
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover...
06/19/2026
Radiopharmaceutical Education Institute
David Cade, MD
Videos
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
David Cade, MD
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the...
06/19/2026
Radiopharmaceutical Education Institute
Neeraj Agarwal, MD
Videos
TALAPRO-3 Establishes Talazoparib Plus Enzalutamide as a New Standard for HRR-Altered Metastatic Hormone-Sensitive Prostate Cancer
06/18/2026
Neeraj Agarwal, MD
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses...
06/18/2026
Oncology
Michael Morris, MD
Videos
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
06/18/2026
Michael Morris, MD
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses...
06/18/2026
Radiopharmaceutical Education Institute
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
Mary-Ellen Taplin, MD
Videos
Phase 3 PROTEUS Trial Establishes New Standard of Care for High-Risk Localized Prostate Cancer
05/31/2026
Mary-Ellen Taplin, MD
Mary-Ellen Taplin, MD, discusses the final analysis of the phase 3 PROTEUS trial, which demonstrated that perioperative apalutamide plus ADT improved pathologic responses and metastasis-free survival in patients with high-risk localized or...
Mary-Ellen Taplin, MD, discusses the final analysis of the phase 3 PROTEUS trial, which demonstrated that perioperative apalutamide plus ADT improved pathologic responses and metastasis-free survival in patients with high-risk localized or...
Mary-Ellen Taplin, MD, discusses...
05/31/2026
Oncology
Mark Garzotto, MD
Videos
Intratumoral Adenoviral Therapy Combined With Radiation in Prostate Cancer
05/27/2026
Mark Garzotto, MD
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a...
05/27/2026
Oncology
Rana McKay, MD
Videos
Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer
05/19/2026
Rana McKay, MD
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses...
05/19/2026
Oncology
Alexander Wyatt, PhD
Videos
Clonal Hematopoiesis Expansion Following 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
02/26/2026
Alexander Wyatt, PhD
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses...
02/26/2026
Radiopharmaceutical Education Institute
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use